Altoida

Altoida operates in the digital health sector, focusing on the assessment of cognitive function through an innovative augmented reality platform. The company serves healthcare professionals, particularly neurologists, by providing tools to screen and monitor cognitive outcomes in patients. Utilizing a self-learning machine learning algorithm, Altoida's technology evaluates functional cognitive aptitude via an iOS and Android-based application. This assessment can be conducted conveniently at home or in the office, with results automatically transmitted to practitioners to assist in diagnosis. The Altoida Medical Device (AMD) is a class II medical device that helps classify patients as healthy, at risk, or with Mild Cognitive Impairment (MCI), acting as a digital biomarker. The business model likely involves selling or licensing its technology to healthcare providers and institutions, generating revenue through these partnerships. The market for Altoida's services includes the growing field of digital medicine, with a focus on neurodegenerative diseases. By offering a gamified and efficient assessment process, Altoida aims to delay and prevent the onset of MCI, potentially reducing the cost of care. Keywords: augmented reality, cognitive assessment, neurodegenerative diseases, digital biomarkers, healthcare, machine learning, medical device, cognitive function, MCI, gamified testing.